FCER1G inhib 
Welcome,         Profile    Billing    Logout  
 0 Companies  0 Products   0 Products   0 Diseases   0 Trials   0 News 


1234»
  • ||||||||||  melphalan / Generic mfg.
    Melphalan-treated multiple myeloma cells exhibit a senescent-like dormancy phenotype (Section 15) -  Mar 5, 2024 - Abstract #AACR2024AACR_5624;    
    This phenotype is associated with longer durable response, suggesting that activation of TIS may be a strategy to extend PFS. Further, senolytic therapy may be a novel approach to eliminate dormant MM cells and prevent relapse.
  • ||||||||||  In vivo immune cell programming using mRNA-LNP chimeric antigen receptors (Section 2) -  Mar 5, 2024 - Abstract #AACR2024AACR_4195;    
    Taken together, we present CAR designs that achieve expression and function in targeted immune cell populations, capable of eliciting anti-tumor efficacy against multiple target antigens by leveraging innate and adaptive immune responses, and demonstrating a class of novel CAR designs to overcome limitations faced by current in vivo mRNA/LNP delivery strategy. A phase I clinical trial is currently on-going to assess the safety and preliminary efficacy of CD89-based CAR against TROP2+ epithelial malignancies.
  • ||||||||||  IMPAIRED CD45RO-CCR7+ NA (Hall 5) -  Feb 14, 2024 - Abstract #EBMT2024EBMT_1803;    
    Both chemotypes covalently modify SYK-tSH2 and inhibit its interaction with FCER1G p-ITAM, however, these compounds lack selectivity and this limits their utility as chemical tools. In pediatric AML patients, CD45RO-CCR7+ na
  • ||||||||||  Preclinical, Journal:  Genome-wide association studies for diarrhoea outcomes identified genomic regions affecting resistance to a severe enteropathy in suckling rabbits. (Pubmed Central) -  Dec 28, 2023   
    The QTL region on OCU13 encompasses several genes that encode members of a family of immunoglobulin Fc receptors (FCER1G, FCRLA, FCRLB and FCGR2A) involved in the immune innate system, which might be important candidate genes for this pathogenic condition. The results obtained in this study demonstrated that resistance to an enteropathy occurring in suckling rabbits is in part genetically determined and can be dissected at the genomic level, providing DNA markers that could be used in breeding programmes to increase resistance to enteropathies in meat rabbits.
  • ||||||||||  Biomarker, Journal:  Diagnostic biomarker for type 2 diabetic peripheral neuropathy via comprehensive bioinformatics analysis. (Pubmed Central) -  Nov 29, 2023   
    This study improves our understanding of the molecular mechanisms in AR via comprehensive strategies and provides potential diagnostic biomarkers and therapeutic targets of AR. Our findings demonstrated FCER1G, PTK2B, and SYK are potential diagnostic biomarkers and therapeutic targets for DPN, which provides new insight into DPN pathogenesis and therapies.
  • ||||||||||  Activating Fc-gamma Receptors Mediate Sciatic Nerve Injury-induced Neuropathic Pain (WCC Halls A-C) -  Nov 3, 2023 - Abstract #Neuroscience2023NEUROSCIENCE_10354;    
    These results indicate that the microglial complex of the SDH plays an important role in the development of neuropathic pain in chronic constriction injury mice. The findings may provide novel insights into potential therapeutic targets for neuropathic pain.
  • ||||||||||  Journal:  Phosphorylation of spleen tyrosine kinase (Syk) at Y346 negatively regulates ITAM-mediated signaling and function in platelets. (Pubmed Central) -  Jul 31, 2023   
    Despite a clear effect of Syk Y346F on GPVI-mediated signaling and cellular responses, there was no effect of this mutation on hemostasis as measured by tail-bleeding times, although the time to thrombus formation determined using the ferric chloride injury model was reduced. Thus, our results indicate a significant effect of Syk Y346F on platelet activation and responses in vitro and reveal its complex nature manifesting itself by the diversified translation of platelet activation into physiological responses in vivo.
  • ||||||||||  Efforts toward discovering inhibitors of the SYK SH2 (Virtual) -  Jul 6, 2023 - Abstract #AAIC2023AAIC_7761;    
    Our work presented a thorough interpretation of TIICs and IRGs for illustrating and discovering new potential immune checkpoints in bone metastases of PCa. Through the TREAT-AD program, we have explored the SYK
  • ||||||||||  Journal, PD(L)-1 Biomarker, IO biomarker:  Peripheral immune mapping and multi-omics analysis in PD-1 inhibitor-induced myocarditis. (Pubmed Central) -  May 19, 2023   
    Meanwhile, the peripheral inflammatory response was exacerbated in patients, accompanied by upregulation of exocytosis as well as increased levels of multiple lipids. We provide a comprehensive overview of the composition, gene profiles, and pathway signatures of CD3+ T cell driven by PD-1 inhibitor-induced myocarditis, as well as illustrate clinical features and multiomic characteristics, providing a unique perspective on disease progression and therapy in clinical practice.
  • ||||||||||  Journal:  Comparative genomic and transcriptomic analyses reveal the impacts of genetic admixture in Kazaks, Uyghurs, and Huis. (Pubmed Central) -  Mar 24, 2023   
    We found the lack of SYK expression could improve target cell conjugation through enhanced CD2 expression or limit SHP-1-mediated inhibition of CD16A signaling, leading to enhanced cytotoxicity and cytokine production. Furthermore, differentially expressed genes between the populations were identified, many of which could be explained by the population-specific regulatory properties, including genes related to health concerns (e.g., AHI1 between Kazak and Uyghurs [P < 6.92